Background: Most of patients harboring EGFR activating mutations will inevitably acquire resistance to EGFR-TKI after 6-12 months of treatment. The T790M mutation in exon 20 of EGFR gene is the main cause of drug resistance, accounting for about 50%. The third-generation TKI targeting T790M mutation has been marketed and used in clinical practice, such as Osimertinib (AZD9291), but there are still nearly 50% of TKI resistance mechanisms unknown or currently lack of clinical approaches for reversing drug resistance. Therefore, exploring the molecular mechanism of T790M-negative EGFR-TKI secondary drug resistance has become a hot spot in lung cancer research. A growing number of studies found that microRNA (miRNA) plays an important role in the regulation of acquired drug resistance of EGFR-TKI, and it is expected to reverse acquired resistance of EGFR TKIs. Method: Cell viabilities of PC9 and PC9/BB4 cells was detected by CCK-8 method, the EdU method was used to detect cell proliferation, cell apoptosis was detected by FACS, and plate colony assay was used to detect colony formation ability. Western blot detected to difference of EGFR downstream signaling pathways in PC9 and PC9/BB4 cells. Results: The results of in vitro experiments indicated that miR-338-3p was down-regulated in Gefitinib-sensitive PC9 cell and highly expressed in PC9/BB4 resistant cells. Up-regulation or down-regulation of miR-338-3p, respectively, can alter the effect of Gefitinib on the survival, proliferation, apoptosis and clonality of PC9 and PC9/BB4 cells, and can regulate the activity of p-Akt and p-Erk1/2 protein, indicating miR -338-3p promotes EGFR-TKI resistance in non-small cell lung cancer by activating EGFR downstream signaling pathway. Using bioinformatics software to predict and confirm by dual luciferase reporter system, PTPN12 is a downstream target gene of miR-338-3p. PTPN12 protein is highly expressed in PC9 cells, low in PC9/BB4 cells, and can interfere with Gefitinib sensitivity after interfering with PTPN12 expression level in PC9 and PC9/BB4 cells, respectively. In vitro experiments demonstrated that miR-338-3p activates EGFR downstream PI3K/Akt and Ras/Raf/Erk signaling pathways by targeting PTPN12, and promote Gefitinib resistance in nonsmall cell lung cancer. Further study showed that down-regulation of miR-338-3p by miR-338-3p antagomir reversed the resistance of PC9/BB4 xenografts to Gefitinib by activating PTPN12. Conclusion: We conclude that alteration of miR-338-3p/PTPN12 expression as a novel mechanism for EGFR-TKI resistance in NSCLC. miR-338-3p/PTPN12 could serve as a therapeutic target for overcoming EGFR-TKI resistance in NSCLC.
Background: Most of patients harboring EGFR activating mutations will inevitably acquire resistance to EGFR-TKI after 6-12 months of treatment. The T790M mutation in exon 20 of EGFR gene is the main cause of drug resistance, accounting for about 50%. The third-generation TKI targeting T790M mutation has been marketed and used in clinical practice, such as Osimertinib (AZD9291), but there are still nearly 50% of TKI resistance mechanisms unknown or currently lack of clinical approaches for reversing drug resistance. Therefore, exploring the molecular mechanism of T790M-negative EGFR-TKI secondary drug resistance has become a hot spot in lung cancer research. A growing number of studies found that microRNA (miRNA) plays an important role in the regulation of acquired drug resistance of EGFR-TKI, and it is expected to reverse acquired resistance of EGFR TKIs. Method: Cell viabilities of PC9 and PC9/BB4 cells was detected by CCK-8 method, the EdU method was used to detect cell proliferation, cell apoptosis was detected by FACS, and plate colony assay was used to detect colony formation ability. Western blot detected to difference of EGFR downstream signaling pathways in PC9 and PC9/BB4 cells. Results: The results of in vitro experiments indicated that miR-338-3p was down-regulated in Gefitinib-sensitive PC9 cell and highly expressed in PC9/BB4 resistant cells. Up-regulation or down-regulation of miR-338-3p, respectively, can alter the effect of Gefitinib on the survival, proliferation, apoptosis and clonality of PC9 and PC9/BB4 cells, and can regulate the activity of p-Akt and p-Erk1/2 protein, indicating miR -338-3p promotes EGFR-TKI resistance in non-small cell lung cancer by activating EGFR downstream signaling pathway. Using bioinformatics software to predict and confirm by dual luciferase reporter system, PTPN12 is a downstream target gene of miR-338-3p. PTPN12 protein is highly expressed in PC9 cells, low in PC9/BB4 cells, and can interfere with Gefitinib sensitivity after interfering with PTPN12 expression level in PC9 and PC9/BB4 cells, respectively. In vitro experiments demonstrated that miR-338-3p activates EGFR downstream PI3K/Akt and Ras/Raf/Erk signaling pathways by targeting PTPN12, and promote Gefitinib resistance in nonsmall cell lung cancer. Further study showed that down-regulation of miR-338-3p by miR-338-3p antagomir reversed the resistance of PC9/BB4 xenografts to Gefitinib by activating PTPN12. Conclusion: We conclude that alteration of miR-338-3p/PTPN12 expression as a novel mechanism for EGFR-TKI resistance in NSCLC. miR-338-3p/PTPN12 could serve as a therapeutic target for overcoming EGFR-TKI resistance in NSCLC. Keywords: EGFR, TKI, lung cancer, PTPN12; miR-338-3p P078 Pneumonia in Ventilated Patients (Tanta University Hospitals) R. Elkolaly Chest, Tanta University, Tanta/EG Background: In spite of different ICU admission causes, ventilatorassociated pneumonia (VAP) is still a common cause of mortality and morbidity in intubated patients and antagonize the obvious progress in diagnostic modalities and management advances of these infections. Method: One year study (April 2015 to March 2016), including patients admitted to ICU with different causes of ventilation, patients who needed invasive ventilation were included in the study. All patients were subjected to: history taking, clinical general and local chest examination, chest radiology, arterial blood gases (ABG), erythrocyte sedimentation rate (ESR), complete blood count (CBC), liver and kidney functions, tracheal aspirate and its bacteriologic examination by stain and culture. And also recording of onset of VAP and duration of ICU stay, regular recording of patient vital signs, oxygen saturation, patient position and used ventilator modes. Results: It is one of statistical studies that began recently to trace infection incidence in national hospitals ICUs. Among 222 admitted patients; only 38.4% fulfilled the criteria of VAP. Admission was due to cardiovascular impairment, cardiac arrest, respiratory failure or head trauma. Ventilation mode at VAP time was assisted control (75%) and synchronized intermittent mandatory ventilation (25%), Minimum intubation period was 7 days while maximum period was 37 days. Isolated organisms were pseudomonas (37.5%), Klebsiella (25%), staphylococcus (20.8%) and MRSA (4.2%). Used antibiotics were amikacin, imipenem, vancomycin, levofloxacin, ceftazidime, ticoblanin (29%, 25%, 21%, 12.5%, 8.3% and 4.2% respectively). Minimum period of used antibiotic was 5 days while maximum period was 35 days. Highest incidence of VAP was in February while least was in July. Conclusion: VAP incidence is still high and vary according intubation cause and period and underlying morbidity. More efforts must be done to prevent, diagnose and manage infection early and properly to decrease patients suffering and to decrease burden on the serving hospitals. Background: Retrotranspons are the transposons that integrate into a genome mediated by RNA revere transcription, which makes up about half of the human genome. Long interspersed element-1 (LINE-1; L1) retrotransposition is the only currently known active autonomous genomic event in humans and might cause genetic instability, which was reported to occur with high frequency in a variety of tumor tissues. However, the relationship between L1 retrotranspostion and lung squamous cell carcinoma (LUSC) is unclear. Method: We analyzed RNA sequencing data of 50 tumor/normal pairs of LUSC samples in The Cancer Genome Atlas (TCGA) and screened out 13 L1 retrotransposons with the high occurrence. The somatic L1 retrotransposons were detected in 109 clinical LUSC samples in comparison with their matched adjacent tissue samples, as well as the correlation between expression of L1 retrotransposon genes and patients' clinical-pathological parameters. Then we focused on L1-FGGY and explored its regulation on cell proliferation, apoptosis, migration and invasion in vitro, as well as its roles on promoting tumorigenesis in vivo. We also applied two nonnucleosidic reverse transcriptase inhibitors, nevirapine (NVR) and efavirenz (EFV) both in vitro and in vivo, to investigate whether pharmacological modulation of endogenous reverse transcriptase activity may represent a novel approach in the treatment of LUSC. Results: We observed somatic L1 retrotransposition in 90% of tumor samples. Thirteen high frequent L1 retrotranspositions were identified and further validated in 5 lung cancer cell lines as well an independent cohort of LUSC tumor samples coupled with matched
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